Perspectives
No to Greed
Abstract
The pharmaceutical industry has produced many marvels, drugs that at their best can be lifesaving. There are, however, instances in which company profit motives can become so egregious that they are detrimental to public health. In my opinion, we are witnessing a potentially catastrophic example of this with Gilead Sciences’ direct-acting antiviral sofosbuvir (Sovaldi), a treatment for the hepatitis C virus (HCV).This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;349:g3808.
2. Centers for Disease Control and Prevention. Hepatitis C factsheet. http://www.cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf. Published 2010. Accessed September 1, 2014.
3. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090-1101.
4. Kabiri M, Jazwinski AB, Roberts MS, et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-180.
5. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
6. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
7. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Initial treatment of HCV infection in patients starting treatment. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment. Accessed September 1, 2014.
8. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59:1692-1705.
9. Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-675.
10. Messori A, Maratea D, Fadda V, et al. Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naBve patients with genotype 1 HCV infection in Italy. Aliment Pharmacol Ther 2014;40:217-218.
11. Ollendorf DA, Tice JA, Pearson SD. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Intern Med 2014;174:1170-1171.
12. Kaczmarek S. The impact of new hepatitis C drug therapy on individual Medicare Part D spending. http://www.pcmanet.org/images/stories/uploads/2014/partdpremiumstudymilliman.pdf. Published July 2014. Accessed September 1, 2014.
13. Gilead Sciences. Gilead Sciences announces second quarter 2014 financial results. http://www.gilead.com/news/press-releases/2014/7/gilead-sciences-announces-second-quarter-2014-financial-results. Published July 23, 2014. Accessed September 1, 2014.
14. Bach P. Cancer: unpronounceable drugs, incomprehensible prices. http://www.forbes.com/sites/matthewherper/2014/08/13/cancer-unpronounceable-drugs-incomprehensible-prices/. Published August 13, 2014. Accessed September 1, 2014
